Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

Advanced Stage ◽

Oncology Group ◽

Disease Extent ◽

Oncology Group Study ◽

Secondary Cytoreductive Surgery

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2016.04.534 ◽

2016 ◽

Vol 141 ◽

pp. 207-208

Author(s):

P.G. Rose ◽

J. Java ◽

M.A. Morgan ◽

A.A. Secord ◽

J. Kesterson ◽

...

Keyword(s):

Overall Survival ◽

Cytoreductive Surgery ◽

Gynecologic Oncology ◽

Oncology Group ◽

Disease Extent ◽

Oncology Group Study ◽

Secondary Cytoreductive Surgery

Secondary Cytoreductive Surgery at Second-Look Laparotomy in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.1997.4806 ◽

1997 ◽

Vol 66 (2) ◽

pp. 171-178 ◽

Cited By ~ 45

Author(s):

Laura Williams ◽

Virginia L. Brunetto ◽

Edgardo Yordan ◽

Philip J. DiSaia ◽

William T. Creasman

Keyword(s):

Ovarian Cancer ◽

Cytoreductive Surgery ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Oncology Group ◽

Oncology Group Study ◽

Secondary Cytoreductive Surgery ◽

Second Look

Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)

BMC Cancer ◽

10.1186/s12885-019-5514-7 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 4

Author(s):

Young Shin Chung ◽

Sang-Yoon Park ◽

Jung-Yun Lee ◽

Jeong-Yeol Park ◽

Jeong-Won Lee ◽

...

Keyword(s):

Ovarian Cancer ◽

Neoadjuvant Chemotherapy ◽

Gynecologic Oncology ◽

Serous Carcinoma ◽

High Grade ◽

Advanced Stage ◽

Oncology Group ◽

Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.01.008 ◽

2012 ◽

Vol 125 (2) ◽

pp. 421-426 ◽

Cited By ~ 32

Author(s):

Jennifer M. Rubatt ◽

Kathleen M. Darcy ◽

Chunqiao Tian ◽

Franco Muggia ◽

Rajiv Dhir ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Clinical Outcomes ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Oncology Group ◽

Oncology Group Study ◽

Pre Treatment ◽

Tumor Expression

The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.11.032 ◽

2012 ◽

Vol 124 (3) ◽

pp. 379-382 ◽

Cited By ~ 32

Author(s):

Vivian E. von Gruenigen ◽

Helen Q. Huang ◽

Karen M. Gil ◽

Heidi E. Frasure ◽

Deborah K. Armstrong ◽

...

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Overall Survival ◽

Adjuvant Chemotherapy ◽

Gynecologic Oncology ◽

Life Domains ◽

Oncology Group ◽

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D

Journal of Gynecologic Oncology ◽

10.3802/jgo.2019.30.e112 ◽

2019 ◽

Vol 30 (6) ◽

Cited By ~ 2

Author(s):

Jung-Yun Lee ◽

Jae Weon Kim ◽

Myong Cheol Lim ◽

Sunghoon Kim ◽

Hee Seung Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Oncology Group ◽

Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.11.013 ◽

2021 ◽

Author(s):

Nefertiti C. duPont ◽

Danielle Enserro ◽

Mark F. Brady ◽

Katherine Moxley ◽

Joan L. Walker ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Gynecologic Oncology ◽

Prognostic Significance ◽

Advanced Stage ◽

Oncology Group ◽

Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.11.022 ◽

2012 ◽

Vol 124 (3) ◽

pp. 575-581 ◽

Cited By ~ 56

Author(s):

Chunqiao Tian ◽

Christine B. Ambrosone ◽

Kathleen M. Darcy ◽

Thomas C. Krivak ◽

Deborah K. Armstrong ◽

...

Keyword(s):

Ovarian Cancer ◽

Clinical Outcomes ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Common Variants ◽

Oncology Group ◽

Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.07.015 ◽

2020 ◽

Vol 159 (1) ◽

pp. 79-87

Author(s):

Krishnansu S. Tewari ◽

Michael W. Sill ◽

Robert L. Coleman ◽

Carol Aghajanian ◽

Robert Mannel ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Phase Ii ◽

Gynecologic Oncology ◽

Recurrent Ovarian Cancer ◽

Oncology Group ◽

Oncology Group Study ◽

Randomized Phase Ii

Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.02.009 ◽

2009 ◽

Vol 113 (3) ◽

pp. 341-347 ◽

Cited By ~ 26

Author(s):

John Farley ◽

Sartoru Fuchiuji ◽

Kathleen M. Darcy ◽

Chunqiao Tian ◽

William J. Hoskins ◽

...

Keyword(s):

Overall Survival ◽

Gynecologic Oncology ◽

Progression Free Survival ◽

Advanced Stage ◽

Oncology Group ◽

Free Survival ◽

Oncology Group Study ◽

Ovarian Cancers ◽

Erbb2 Amplification